RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC.
Ontology highlight
ABSTRACT: The era of precision medicine has resulted in the identification of a number of genomic alterations that can be targeted with novel therapies. In lung adenocarcinomas, a histology structure that accounts for nearly 50% of all cases of lung cancer, and a number of genomic targets have been linked with effective targeted therapies. For patients with advanced-stage lung adenocarcinomas, molecular testing is now a standard part of diagnostic workup; for patients that have specific driver molecular events, targeted therapies have resulted in substantial improvement in efficacy without excessive toxicity. RET gene fusions are present in approximately 1% to 2% of NSCLC. It is emerging as a new targetable driver for this population. Despite sensitivity to platinum-based chemotherapy and con
SUBMITTER: Osta BE
PROVIDER: S-EPMC8474418 | biostudies-literature | 2020 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA